Drugs / ANV419
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05869539 | Jun 2023 → Apr 2026 overdue | melanoma | University Hospital, Basel, Switzerland | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05641324 | Feb → Jul 2023 | plasma cell myeloma | Anaveon AG | Terminated | No outcome recorded |
| Phase 1 | NCT04855929 | May 2021 → Jul 2024 | lung cancer | Anaveon AG | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05578872 | Dec 2022 → Aug 2024 | cutaneous melanoma, metastatic melanoma | Anaveon AG | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06630611 | Jan 2025 → Sep 2029 expected | cervical cancer, melanoma, non-small cell lung carcinoma | Vall d'Hebron Institute of Oncology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANV419 | “ANV419 is a novel IL-2 agent, which has been developed as a preferentially IL-2Rβγ directed fusion protein with a longer half-life.” NCT06630611 ↗ |
| Modality | Protein / enzyme biologic | “ANV419 is a stable antibody-cytokine fusion protein” PMID 38243906 ↗ Nov 2023 |
| Route | Intravenous | “ANV419 was administered by intravenous infusion once every 2 weeks” PMID 38243906 ↗ Nov 2023 |